Keytruda, Opdivo, Tecentriq and Ocrevus would loss a lifecycle management strategy under CMS's proposal to prevent manufacturers from treating newer subcutaneous formulations of biologics as separate products for Medicare negotiation purposes.
Keytruda, Opdivo, Tecentriq and Ocrevus would loss a lifecycle management strategy under CMS's proposal to prevent manufacturers from treating newer subcutaneous formulations of biologics as separate products for Medicare negotiation purposes.